Molecular structure of Sulthiame, CAS Number: 61-56-3
Sulthiame (CAS 61-56-3)
Alternate Names:
4-(Tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)benzenesulfonamide; 4-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide S,S-Dioxide; 2-(p-Sulfamoylphenyl)-tetrahydro-2H-1,2-thiazine 1,1-Dioxide
Application:
Sulthiame is a benzenesulfonamide derivative
CAS Number:
61-56-3
Molecular Weight:
290.36
Molecular Formula:
C10H14N2O4S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sulthiame is a benzenesulfonamide derivative that acts as an inhibitor of the enzyme carbonic anhydrase. Sulthiame, also referred to as Riker 594 and Ospolot, belongs to the benzenesulfonamide derivative family. Its primary function involves inhibiting the enzyme carbonic anhydrase.
Sulthiame (CAS 61-56-3) References
- Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. | Leniger, T., et al. 2002. Epilepsia. 43: 469-74. PMID: 12027906
- Sulthiame in childhood epilepsy. | Ben-Zeev, B., et al. 2004. Pediatr Int. 46: 521-4. PMID: 15491376
- Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit. | Swiderska, N., et al. 2011. Seizure. 20: 805-8. PMID: 21924927
- Sulthiame add-on therapy in children with focal epilepsies associated with encephalopathy related to electrical status epilepticus during slow sleep (ESES). | Fejerman, N., et al. 2012. Epilepsia. 53: 1156-61. PMID: 22509732
- Sulthiame monotherapy for epilepsy. | Milburn-McNulty, P., et al. 2014. Cochrane Database Syst Rev. 2014: CD010062. PMID: 24609897
- Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. | Patsalos, PN., et al. 2018. Ther Drug Monit. 40: 526-548. PMID: 29957667
- Sulthiame add-on therapy in children with Lennox-Gastaut syndrome: A study of 44 patients. | Caraballo, RH., et al. 2018. Seizure. 62: 55-58. PMID: 30286409
- Sulthiame add-on therapy for epilepsy. | Bresnahan, R., et al. 2019. Cochrane Database Syst Rev. 8: CD009472. PMID: 31453633
- A fully validated HPLC-UV method for determination of sulthiame in human serum/plasma samples. | Madej, K., et al. 2021. Biomed Chromatogr. 35: e5002. PMID: 33058183
- Sulthiame impairs mitochondrial function in vitro and may trigger onset of visual loss in Leber hereditary optic neuropathy. | Reinert, MC., et al. 2021. Orphanet J Rare Dis. 16: 64. PMID: 33541401
- Effects of sulthiame on seizure frequency and EEG in children with electrical status epilepticus during slow sleep. | Topçu, Y., et al. 2021. Epilepsy Behav. 116: 107793. PMID: 33549940
- Clonic seizures, continuous spikes-and-waves during slow sleep, choreoathetosis and response to sulthiame in a child with FRRS1L encephalopathy. | Hadi, DA., et al. 2022. Brain Dev. 44: 44-49. PMID: 34483011
- Use of sulthiame as add-on therapy in children with non-self-limited focal epilepsies of childhood. | Caraballo, R., et al. 2023. Epilepsy Behav. 143: 109220. PMID: 37119578
- Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. | Battino, D., et al. 1995. Clin Pharmacokinet. 29: 341-69. PMID: 8582119
- Sulthiame-associated mild compensated metabolic acidosis. | Tröger, U., et al. 1996. Int J Clin Pharmacol Ther. 34: 542-5. PMID: 8996849
Inhibitor of:
CA I, CA III, CA V, and Carbonic Anhydrases.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sulthiame, 25 mg | sc-474559 | 25 mg | $350.00 | |||
Sulthiame, 250 mg | sc-474559A | 250 mg | $2448.00 |